RxDoctor Payments Data

Jennifer Shurette

Family · Ithaca, NYNPI 1740929652

Payments from drug & device makers

$917in general payments, 2019–2025

Across 39 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$325
  • Radius Health, Inc.$198
  • Xeris Pharmaceuticals, Inc.$66
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$52
  • Bayer$49
  • Neurocrine Biosciences, Inc.$42
  • plus $185 from 8 others

What the payments were for

  • Food & beverage$917100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$917 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$44,720
Medicare patients
264
Services billed
954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$121,331
JardianceEmpagliflozin48$40,668
EliquisApixaban42$40,032
XareltoRivaroxaban29$29,250
Abiraterone Acetate11$25,935
MounjaroTirzepatide13$16,994
LinzessLinaclotide13$16,664
FarxigaDapagliflozin Propanediol19$14,937
EntrestoSacubitril/Valsartan11$13,228
MyrbetriqMirabegron14$9,109
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,387
Repatha SureclickEvolocumab15$8,196
Rosuvastatin Calcium283$7,238
Humalog Kwikpen U-200Insulin Lispro12$6,452
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$5,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$19$16,99413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.

Other family in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →